ipatasertib
ipatasertib: sourced relationships with 1 company · 8 clinical trials tracked.
ipatasertib evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could ipatasertib → ARRY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ARRAY BIOPHARMA INC (ARRY) | Phase 3 |
Clinical Trial Registry Records (8)
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
Primary endpoint: Objective response rate (ORR)
An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
Primary endpoint: Number of Participants With Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Primary endpoint: Accrual of patients to ComboMATCH treatment trials
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Primary endpoint: Investigator-assessed overall response rate (ORR) of each biomarker cohort
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)
Primary endpoint: Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Primary endpoint: All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
Primary endpoint: Objective Response Rate (ORR)
Molecular Analysis for Therapy Choice (MATCH)
Primary endpoint: Objective response rate (ORR)
Frequently asked questions
Which companies have sourced relationships with ipatasertib?
ipatasertib has dated SEC/FDA relationship records for ARRAY BIOPHARMA INC.
How many clinical trials involve ipatasertib?
BioSniper tracks 8 clinical trials involving ipatasertib.